OVIOPEPTIDES

Exclusive Offer

Free Bacteriostatic Water

Sign up and get a free bacteriostatic water added to your next order, automatically.

Research Use OnlyGet free bacteriostatic water added to your next order when you join the list.

BPC-157 vs TB-500 — Canada Research Comparison

By Dr. Elena Morozova, PhDReviewed by Dr. Elena Morozova, PhDPublished April 11, 2026Last reviewed April 11, 20263 min read
Quick answer

BPC-157 is a 15-residue gastric-juice-derived peptide with proposed NO and VEGFR2 effects, while TB-500 is the actin-binding heptapeptide fragment of thymosin β4 — both are preclinical and neither is approved in Canada.

At a glance

BPC-157 and TB-500 are the two most widely marketed "healing" research peptides in Canada, and they are frequently grouped together despite having almost nothing in common biochemically. One is derived from a protective sequence identified in human gastric juice. The other is a defined fragment of an actin-binding protein. Both are preclinical. Neither is approved.

Key facts

FeatureBPC-157TB-500
Full nameBody Protection Compound 157Thymosin β4 fragment (17–23)
SequenceGEPPPGKPADDAGLV (15 residues)Ac-LKKTETQ-NH₂ (7 residues)
OriginPartial sequence from human BPCActive motif of thymosin β4
Molecular weight~1,419 g/mol~889.98 g/mol
Primary targetNone confirmedG-actin (sequestering)
Proposed pathwaysNO, VEGFR2, growth-factor modulationActin dynamics, cell migration, angiogenesis
Human trialsEssentially noneEarly trials of related Tβ4 forms (RGN-137/259)
Approval (Canada)NoneNone
Research baseConcentrated (Sikiric group, Croatia)Distributed across independent groups

Origin and structure

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of "body protection compound", a protein fraction identified in human gastric juice by the Sikiric group. The 15-residue synthetic fragment has been the subject of most of the preclinical literature, although it is not a naturally circulating peptide in its own right.

TB-500 is the acetylated heptapeptide Ac-LKKTETQ-NH₂ corresponding to residues 17–23 of thymosin β4. It was identified by Van Troys et al. as the minimal actin-binding motif of the parent molecule and is used as a soluble, synthetically tractable proxy for full-length Tβ4 in tissue- repair research.

Mechanistic contrast

TB-500 has a defined biochemical handle: G-actin sequestering. That pathway is well characterised and provides a plausible bridge to reported effects on cell migration, angiogenesis, and wound-bed remodelling in rodent models.

BPC-157 has no confirmed primary receptor. The literature proposes several pathways — nitric oxide signalling, VEGFR2 upregulation, NF-κB modulation, and several growth-factor interactions — but these are indirect effects observed in specific assays rather than evidence of a single binding partner.

Evidence quality

Both peptides are preclinical-only. The key difference is how the literature is distributed. BPC-157 publications are dominated by a single Croatian research group, which means the body of evidence is large but not well replicated by independent investigators. Thymosin β4 and its fragments have been studied by a broader set of groups, and related Tβ4 preparations (RGN-137, RGN-259) have reached early human trials for wound and corneal indications — not TB-500 specifically, but clinically adjacent work.

Regulatory status

Neither compound is approved in Canada or elsewhere. Neither has completed a controlled Phase 2 trial in the exact research-peptide form sold to Canadian labs.

Frequently asked questions

What is the mechanistic difference between BPC-157 and TB-500?
TB-500 is the seven-residue actin-binding motif (Ac-LKKTETQ-NH₂) of thymosin β4. Its mechanism is anchored in G-actin sequestering and downstream effects on cell migration and angiogenesis — a well-characterised biochemical pathway. BPC-157 has no confirmed receptor. Proposed mechanisms include nitric oxide pathway modulation, VEGFR2 upregulation, and growth-factor signalling, but none has reached the level of a validated primary target.
How does the published evidence base compare?
Both peptides are preclinical only, but the shape of the literature differs. BPC-157 research is heavily concentrated in a single Croatian research group led by Predrag Sikiric, which accounts for the majority of published rodent studies. Thymosin β4 and TB-500 have a broader distribution of independent investigators and have reached early human trials under the RegeneRx codes RGN-137 (topical) and RGN-259 (ophthalmic) for wound-related indications.
Is either peptide approved in Canada?
No. Neither BPC-157 nor TB-500 has any marketing authorisation from Health Canada, the U.S. FDA, or any other major regulator. Human clinical evidence for both compounds is limited. They are sold in Canada strictly as research chemicals for non-clinical laboratory research.
Are BPC-157 and TB-500 commonly studied together?
In the research-peptide literature the two are sometimes paired on the assumption that their mechanisms are complementary — TB-500 acting via actin and cell migration, BPC-157 via vascular and growth-factor pathways. There is no published controlled study demonstrating synergy between the two. Any stacked use is extrapolation from separate preclinical datasets.

References

  1. [1]Van Troys M, Dewitte D, Goethals M, et al.. The actin-binding site of thymosin beta 4. EMBO Journal, 1996. PMID: 8610111
  2. [2]Sikiric P, Seiwerth S, Rucman R, et al.. Brain-gut Axis and Pentadecapeptide BPC 157 — Theoretical and Practical Implications. Current Neuropharmacology, 2016. PMID: 26648468
  3. [3]Bock-Marquette I, Saxena A, White MD, et al.. Thymosin β4 and cardiac repair. Nature, 2004. PMID: 15306811
  4. [4]National Center for Biotechnology Information. PubChem CID 9941957 — BPC-157, 2024

Related research